Clinical Trial Update: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib [Phase 2]

View source ↗

Summary

Phase 2 study evaluating brigatinib in patients with anaplastic lymphoma kinase–positive advanced non-small cell lung cancer that progressed on prior ALK inhibi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)

Snippet

Sponsor: Ariad Pharmaceuticals | Conditions: ALK-positive Advanced NSCLC | Phase 2 | Status: COMPLETED | Results posted: 2021-10-25